Scarica l'app Stockscreener
3.70
5.71%
0.20
Precedente Chiudi:
$3.50
Aprire:
$3.56
Volume 24 ore:
6.10M
Relative Volume:
3.01
Capitalizzazione di mercato:
$246.54M
Reddito:
$80.00M
Utile/perdita netta:
$-76.12M
Rapporto P/E:
-3.2272
EPS:
-1.1465
Flusso di cassa netto:
$-63.88M
1 W Prestazione:
+4.23%
1M Prestazione:
-39.24%
6M Prestazione:
-69.57%
1 anno Prestazione:
-41.82%
Intervallo 1D:
$3.46
$3.71
Intervallo di 1 settimana:
$3.43
$3.71
Portata 52W:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.70 | 246.54M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Iniziato | JP Morgan | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - FinancialContent
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Inc (FULC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
Fulcrum plunges after discontinuing lead program - MSN
What's going on with Fulcrum Therapeutics stock on Thursday? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks
Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan
Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan
FULC stock crashes as cancer risk forces its only drug program's end - MSN
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encour - The National Law Review
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - NewMediaWire
Layoff Tracker: Fulcrum axes 85% of staff after walking away from lead asset - BioSpace
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
What's Going On With Fulcrum Therapeutics Stock On Thursday? - Sahm
Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives - The Business Journals
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Reach Out - ACCESS Newswire
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC) - GlobeNewswire
Fulcrum Therapeutics Undertakes Major Restructuring, Explores Strategic Alternatives - TipRanks
Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review - Stock Titan
Fulcrum Therapeutics, Inc. Engages Leerink Partners LLC as Financial Advisor to Assist in Reviewing Potential Strategic Alternatives - marketscreener.com
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire
FULC Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift - Seeking Alpha
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - sharewise.com
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum T - GuruFocus
This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):